{
  "docId": "019de075-0f3e-7563-9ac8-6248b1eac169",
  "docSlug": "df5bd8b83b2912100a1eb82b66046bd0",
  "documentTitle": "Theravance Biopharma | Results Presentation Deck | 41 slides",
  "authorId": "theravance-biopharma",
  "authorName": "Theravance Biopharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 41,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "before_after",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "Uses a before-after framing to show alignment between stated goals and actual performance.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-0f3e-7563-9ac8-6248b1eac169/5",
  "deckHref": "/decks/019de075-0f3e-7563-9ac8-6248b1eac169",
  "deckJsonHref": "/decks/019de075-0f3e-7563-9ac8-6248b1eac169.json",
  "deckAnchorHref": "/decks/019de075-0f3e-7563-9ac8-6248b1eac169#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.6,
        "y": 0.25
      },
      "kind": "list",
      "text": "Progress: Total net sales up 8%; Retail starts up 61%; Market shares at new highs; PIFR-2 study on track",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b69e75f-288f-41dd-83ae-70029c097b64",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.08,
        "y": 0.25
      },
      "kind": "list",
      "text": "Target: Continue YUPELRI Net Sales growth; Complete PIFR-2 study",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ab84af5f-0201-4c7a-8268-4191e3c772b0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "1. In the US, Viatris is leading the commercialization of YUPELRI... PIFR, peak inspiratory flow rate.",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2d7a170d-953f-4897-b6b7-d14891a12054",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.13
      },
      "kind": "title",
      "text": "Strong Demand Growth in Both Hospital and Community Settings",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b12ffcd-cec6-4180-9684-f0a0391cd88a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.5,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Progress Against 2023 YUPELRI® Targets",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5ae1b1b9-aba7-482d-9440-2f1fe37a67ae",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Before-After-Bridge",
      "slug": "before-after-bridge",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "6d416347-8e6d-495a-abc0-aa67dd74b637",
      "evidence": "Progress: Total net sales up 8%; Retail starts up 61%; Market shares at new highs; PIFR-2 study on track",
      "confidence": 0.7
    },
    {
      "name": "Before/after framing",
      "slug": "before-after-framing",
      "agent": null,
      "layer": "slide",
      "matchId": "104a1a94-0056-4efb-8cf5-5e64f1cac4f5",
      "evidence": "Progress Against 2023 YUPELRI® Targets",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "before-after-framing",
      "slug": null,
      "matchId": "fdc90c08-6bbf-4ba7-8573-0cfbc47c045c",
      "evidence": "The slide explicitly contrasts 'Target' and 'Progress' columns to demonstrate success.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 40,
      "from": 5,
      "beatId": "18f97180-6c3c-4b05-a378-979222504b06",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Before-After",
      "beatSlug": null,
      "evidence": "Multiple slides show progress and growth using before-after comparisons.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}